Sodertalje, Sweden

Anders Bogevig


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2010-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Anders Bogevig in Pharmaceutical Research

Introduction

Anders Bogevig is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical research, particularly in the development of novel therapeutic compounds. With a total of 2 patents to his name, Bogevig's work focuses on innovative solutions for various medical conditions.

Latest Patents

Among his latest patents are the Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy. These patents disclose novel compounds that are designed to inhibit the enzyme MPO, making them particularly useful in treating or preventing neuroinflammatory disorders, cardiovascular disorders, and respiratory disorders. The compounds are presented in a specific formula, along with processes for their preparation and compositions containing them.

Career Highlights

Anders Bogevig is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on the development of innovative therapies that address critical health issues. His contributions have been instrumental in advancing the company's research initiatives.

Collaborations

Throughout his career, Bogevig has collaborated with several esteemed colleagues, including Yvonne Lo-Alfredsson and Donald Pivonka. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Anders Bogevig's work exemplifies the impact of innovation in pharmaceutical research. His patents and collaborations highlight his commitment to developing effective therapies for complex medical conditions. His contributions continue to shape the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…